BioRestorative Therapies (BRTX) Enterprise Value (2010 - 2025)
BioRestorative Therapies' (BRTX) quarterly Enterprise Value came in at -$3.0 million in Q4 2025, up 72.49% YoY from -$1.7 million in Q4 2024, and up 34.23% on a QoQ basis from -$4.5 million in Q3 2025.
BioRestorative Therapies (BRTX) Enterprise Value (2010 - 2025) Analysis & Trends
BioRestorative Therapies (BRTX) has 15 years of Enterprise Value data on file, last reported at -$3.0 million in Q4 2025.
- Quarterly Enterprise Value rose 72.49% year-over-year to -$3.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$3.0 million (up 72.49% YoY) and the FY2025 annual result came in at -$3.0 million, up 72.49% from the prior year.
- Enterprise Value climbed to -$3.0 million in Q4 2025, from -$4.5 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$1.1 million in Q3 2021 to a low of -$30.5 million in Q1 2024.
- A 5-year average of -$12.2 million and a median of -$12.4 million in 2023 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2021 — Enterprise Value slumped 52220.27% — and 2025, when it jumped 72.49%.
- Tracing BRTX's Enterprise Value over 5 years: stood at -$21.0 million in 2021, then increased by 29.85% to -$14.7 million in 2022, then increased by 24.97% to -$11.1 million in 2023, then advanced by 3.01% to -$10.7 million in 2024, then jumped by 72.49% to -$3.0 million in 2025.
- The last three Enterprise Value figures came in at -$3.0 million (Q4 2025), -$4.5 million (Q3 2025), and -$7.4 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -3.31 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.16 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 2.12 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -18.39 Bn |
| 10 | BioRestorative Therapies | 2.00 Mn | -953,752.60 | 17,964.00 | -2.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -2.95 Mn |
| Sep 30, 2025 | -4.49 Mn |
| Jun 30, 2025 | -7.38 Mn |
| Mar 31, 2025 | -9.11 Mn |
| Dec 31, 2024 | -10.73 Mn |
| Sep 30, 2024 | -13.09 Mn |
| Jun 30, 2024 | -14.68 Mn |
| Mar 31, 2024 | -30.52 Mn |
| Dec 31, 2023 | -11.07 Mn |
| Sep 30, 2023 | -19.60 Mn |
| Jun 30, 2023 | -19.66 Mn |
| Mar 31, 2023 | -12.37 Mn |
| Dec 31, 2022 | -14.75 Mn |
| Sep 30, 2022 | -16.49 Mn |
| Mar 31, 2022 | -19.32 Mn |
| Dec 31, 2021 | -21.03 Mn |
| Sep 30, 2021 | -1.13 Mn |
| Jun 30, 2021 | -1.76 Mn |
| Mar 31, 2021 | -2.50 Mn |
| Dec 31, 2020 | -3.06 Mn |